CMC Planner, Supply Chain (Contract)

Reporting to the Manager, Clinical Supply Chain, the contract CMC Planner, Supply Chain is responsible for managing, planning, executing, and following up on clinical supply chain transactions and shipping for ongoing ALX Oncology (ALX) clinical trials. The CMC Planner will work closely with internal teams, ALX Clinical Operations, and external partners to ensure the seamless flow of Clinical Trial Materials (CTM), including Investigational Products (IP), companion drugs, inventory tracking, and distribution logistics. This position plays a critical role in supporting the clinical development pipeline, ensuring that products are available at the right time and place, with the required quality and compliance.

This is a six-month contract assignment expected to require 40 hours per week. The anticipated pay rate is approximately $50 per hour. Candidates who can work onsite on Mondays and Tuesdays as part of the company’s hybrid work model will be given preference.

Qualified contractors should have experience that includes:

• Clinical trial supply management, including CTM planning, inventory management, forecasting, and global distribution of investigational products (IP).
• Coordinating domestic and international shipments, including import/export requirements, customs documentation, VAT, and Qualified Person (QP) release activities.
• Managing clinical packaging, labeling, storage, depots, transportation, and logistics through contract manufacturing organizations (CMOs) and other external vendors.
• Collaborating cross-functionally with Clinical Operations, Quality Assurance, Regulatory Affairs, Technical Development, and external partners to ensure timely, compliant execution of clinical supply activities.
• Troubleshooting supply chain issues, proactively identifying risks, and implementing effective solutions.
• Working knowledge of GMP, GCP, GDP, IRT systems, and global clinical supply chain regulations.
• Experience working independently in an outsourced vendor management environment, managing multiple priorities and external partners within a fast-paced, highly matrixed biotechnology organization.

About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ ALX Oncology .